Looking for 32+ (tp1) 1.2% risk, stop below X May add with price action will share if I do
Stock above EXMA 200 and still in uptrend Stock is making higher low EXMA 13 is equal EXMA 34 So you can buy target 105.3 stop loss 81.98 Good luck
One of the stocks that came on my scan this week is ARVN. Gapped-Up December 2020 and has since pullback to value zone. Technically, looking prepared to move up again to re-test its January Swing High, however, another earning report is due 17 days time (Earnings may be dynamic and has nothing to do with this technical analysis, be advised accordingly!) N.B - Let...
Arvinas Nearly Doubles on Promising Cancer Drug Results The test results show the Arvinas drugs' potential for treating breast and prostate cancer, Cantor said. Arvinas (ARVN) - Get Report shares blasted off Monday as Cantor Fitzgerald offered bullish comments on the biopharmaceutical company after it reported positive news on its breast and prostate cancer...
After breaking the level of (36) with power . the market did a little pullback. but he was weak. at the moment there is a big probability that he will go around (20)
Short, purely speculative based on chart. Seems to have a nice run to 2.816 Fib. that is plenty on couple of months. Target $28
Arvinas Pharmaceuticals is on a run thanks to FDA approval of phase 1 clinical trials on a new drug. It's above critical resistance levels and appears to have clearance up to 25.60. Personally I won't be taking a position in this one, though. Arvinas's earnings are pretty garbage, and honestly a phase 1 clinical trial doesn't mean much in this industry. We've...
We been long since $12.95 and $21.00. Still long as we do like the prospects of this company; finally looks poised as it did back in Feb..
Higher lows over the past week. Pennies from ATH. Been long since 19's